Baird Lifts PT on Astrana Health (ASTH) Following Q1 Results
Key takeaways
- In its financial results for fiscal Q1 2026 released on May 7, Astrana Health, Inc.
- (NASDAQ:ASTH) is a physician-centric, technology-powered, risk-bearing healthcare management company that operates as an integrated healthcare delivery platform.
- While we acknowledge the potential of ASTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
Baird Lifts PT on Astrana Health (ASTH) Following Q1 Results Noor Ul Ain Rehman Thu, May 14, 2026 at 11:53 PM GMT+7 1 min read ASTH Astrana Health, Inc. (NASDAQ:ASTH) is one of the best small cap stocks to buy for 10x potential. On May 8, Baird lifted the price target on Astrana Health, Inc. (NASDAQ:ASTH) to $45 from $40, maintaining an Outperform rating on the shares. The firm updated its model on the stock after it released its fiscal Q1 2026 financial results, stating that the story is strengthening and the MA margin upside is taking shape. The company also received a rating update from Needham the same day, with the firm lifting the price target on Astrana Health, Inc. (NASDAQ:ASTH) to $41 from $30 and reaffirming a Buy rating on the shares.
In its financial results for fiscal Q1 2026 released on May 7, Astrana Health, Inc. (NASDAQ:ASTH) reported total revenue of $965.1 million, reflecting a 56% year over year growth. It also reported adjusted EBITDA of $66.3 million, up 82% year over year, and free cash flow of $64.1 million, up 372% year over year.
Astrana Health, Inc. (NASDAQ:ASTH) is a physician-centric, technology-powered, risk-bearing healthcare management company that operates as an integrated healthcare delivery platform. It provides services including Multi-Specialty Care, Primary Care, Radiology, Immediate Care, and Laboratory.